Literature DB >> 15741476

Comparison of large versus smaller randomized trials for mental health-related interventions.

Despina G Contopoulos-Ioannidis1, Simon M Gilbody, Thomas A Trikalinos, Rachel Churchill, Kristian Wahlbeck, John P A Ioannidis.   

Abstract

OBJECTIVE: The extent of disagreement between large and smaller randomized, controlled trials on mental health issues is unknown. The authors aimed to compare the results of large versus smaller trials on mental health-related interventions.
METHOD: The authors screened 161 Cochrane and 254 Database of Abstracts of Reviews of Effectiveness systematic reviews on mental health-related interventions. They identified 16 meta-analyses with at least one "large" randomized trial with sample size >800 and at least one "smaller" trial. Effect sizes were calculated separately for large and smaller trials. Heterogeneity was assessed between all studies, within each group (large and smaller studies), and between large and smaller studies.
RESULTS: Significant between-study heterogeneity was seen in five meta-analyses. By random-effects calculations, the results of large and smaller trials differed beyond chance in four meta-analyses (25%). In three of these disagreements (effect of day care on IQ, discontinuation of antidepressants, risperidone versus typical antipsychotics for schizophrenia), the smaller trials showed greater effect sizes than the large trials. The inverse was seen in one case (olanzapine versus typical antipsychotics for schizophrenia). With fixed-effects models, disagreements beyond chance occurred in five cases (31%). In four meta-analyses, the effect size differed over twofold between large and smaller trials. Various quality and design parameters were identified as potential explanations for some disagreements.
CONCLUSIONS: Large trials are uncommon in mental health. Their results are usually comparable with the results of smaller studies, but major disagreements do occur. Both large and smaller trials should be scrutinized as they offer a continuum of randomized evidence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15741476     DOI: 10.1176/appi.ajp.162.3.578

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  7 in total

1.  Are "treatment" bare metal stents superior to "control" bare metal stents? A meta-analytic approach.

Authors:  David M Kent; Thomas A Trikalinos
Journal:  Am Heart J       Date:  2008-01-18       Impact factor: 4.749

2.  Recruitment and enrollment of African Americans and Caucasians in a health promotion trial for persons with serious mental illness.

Authors:  Mona Siddiqui; Lisa A Cooper; Lawrence J Appel; Airong Yu; Jeanne Charleston; Joseph Gennusa; Faith Dickerson; Gail L Daumit
Journal:  Ethn Dis       Date:  2015       Impact factor: 1.847

3.  Neural reactivity to monetary rewards and losses in childhood: longitudinal and concurrent associations with observed and self-reported positive emotionality.

Authors:  Autumn Kujawa; Greg Hajcak Proudfit; Ellen M Kessel; Margaret Dyson; Thomas Olino; Daniel N Klein
Journal:  Biol Psychol       Date:  2014-11-26       Impact factor: 3.251

4.  Influence of Research on Health Policy and Clinical Practice.

Authors:  Hafizur Rahman
Journal:  J Obstet Gynaecol India       Date:  2017-06-07

Review 5.  Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies.

Authors:  Matthew J Page; Julian P T Higgins; Gemma Clayton; Jonathan A C Sterne; Asbjørn Hróbjartsson; Jelena Savović
Journal:  PLoS One       Date:  2016-07-11       Impact factor: 3.240

6.  Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis.

Authors:  Evan Mayo-Wilson; Sofia Dias; Ifigeneia Mavranezouli; Kayleigh Kew; David M Clark; A E Ades; Stephen Pilling
Journal:  Lancet Psychiatry       Date:  2014-10-07       Impact factor: 27.083

Review 7.  Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view.

Authors:  Andreas Kronbichler; Maria Effenberger; Michael Eisenhut; Keum Hwa Lee; Jae Il Shin
Journal:  Autoimmun Rev       Date:  2020-05-03       Impact factor: 9.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.